Juno
Therapeutics Inc. (Nasdaq: JUNO) widened fourth quarter losses more than
expected to $13.68 per share from $9.98 per share in the year ago period but the company noted that ten of its product candidates will
enter clinical development in the next year. The stock price leaped $8.75 to close at $59.68.
Ten Juno products to enter clinical development
March 19, 2015 at 17:42 PM EDT
